A proprietary transdermal delivery system utilizing sufentanil, a potent opioid, for the treatment of chronic pain.
View complete product pipeline
August 07, 2014DURECT Corporation Announces Second Quarter 2014 Financial Results and Update of Programs
July 30, 2014DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call
June 27, 2014DURECT Secures $20 Million Debt Financing
June 09, 2014DURECT to Present at The Wall Street Analyst Forum Institutional Investor Conference
May 16, 2014DURECT Announces POSIDUR™ (SABER®-Bupivacaine) Data Presentation at the International Anesthesia Research Society (IARS) Annual Meeting
May 07, 2014DURECT Announces Participation in Bay Area Prescription Drug Abuse Summit Meeting